[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"metabolic-syndrome-x\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:metabolic-syndrome-x":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,7,0,[8,44,64,104,131,160,190],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100577705","study-for-the-identification-of-a-score-to-assess-intrapancreatic-fat-through-eco-elastography-and-its-correlation-with-metabolic-syndrome-and-insulin-secreting-cells-100577705",false,"NCT06801769","Study for the Identification of a Score to Assess Intrapancreatic Fat Through Eco-Elastography and Its Correlation With Metabolic Syndrome and Insulin-Secreting Cells.","Study for the Identification of a Quantitative Eco-Elastographic Score of Pancreatic Steatosis and Its Correlation With Beta-Cell Function and Metabolic Syndrome.","SPES","Inclusion Criteria:\n\n* Age between 18 and 80 years\n* HbA1c \\\u003C10% or fasting glucose \\\u003C250 mg\u002FdL\n* Ability to understand and provide informed consent regarding the procedures, data collection, and analysis.\n\nExclusion Criteria:\n\n* Age \\\u003C18 years or \\>80 years\n* History of diabetes treated with insulin\n* HbA1c \\>10% or fasting glucose \\>250 mg\u002FdL\n* Pancreatic diseases (solid tumors\u002Fsecretory NETs\u002Fcystic fibrosis; non-secretory NETs and IPMN may be included)\n* Previous pancreatic surgery\n* Moderate anemia (Hb \\\u003C10 mg\u002FdL)\n* Severe liver failure (Child-Pugh C)\n* Non-metabolic causes of NAPLD (e.g., corticosteroid therapy, antiretrovirals, gemcitabine, octreotide, history of hemochromatosis, malnutrition, HBV\u002FHIV infections)\n* Alcohol abuse (\\>30 g\u002Fday of ethanol)\n* Pregnancy and breastfeeding\n* Inability to adequately understand informed consent and study procedures","ALL","18 Years","80 Years",{"count":21,"type":22},100,"ESTIMATED","INTERVENTIONAL",[25],"NA","\\*\\*Brief Summary of the SPES Clinical Study\\*\\*\n\nThe SPES clinical study aims to evaluate the relationship between pancreatic fat accumulation (pancreatic steatosis) and metabolic health. Pancreatic steatosis has been linked to conditions like type 2 diabetes (T2D) and metabolic syndrome, but the underlying mechanisms and its impact on beta-cell function remain poorly understood.\n\nThe primary goal of this study is to develop a quantitative ultrasound elastography score to measure the degree of pancreatic steatosis and explore how this relates to pancreatic beta-cell function and key factors associated with the development of type 2 diabetes and metabolic syndrome.\n\nA secondary goal is to categorize participants into four risk classes for type 2 diabetes based on their metabolic profiles and correlate these classes with the degree of pancreatic steatosis. This may provide insights into individual risk stratification for T2D and related complications.\n\nThe study will enroll 100 participants, aged 18 to 80, attending the Endoscopic Ultrasound Unit at the Fondazione Policlinico Universitario Agostino Gemelli in Rome. Participants will undergo endoscopic ultrasound for various clinical reasons, excluding those with pancreatic tumors, cystic fibrosis, or insulin-treated diabetes. Key inclusion criteria include controlled blood glucose levels (HbA1c \\\u003C 10% or fasting glucose \\\u003C 250 mg\u002FdL) and the ability to understand and provide informed consent.\n\nThe study is interventional but does not involve drugs or medical devices. Participants will attend a visit where medical history, physical measurements (e.g., BMI, waist circumference, blood pressure), glucose tolerance tests, and blood work will be collected. This comprehensive approach aims to better understand the metabolic implications of pancreatic steatosis and its role in type 2 diabetes development.\n\nThe study will last 24 months, including the enrollment period. Findings may contribute to improved risk stratification, prevention, and management strategies for type 2 diabetes and related conditions.",[28,29,30],"Pancreatic Steatosis","Metabolic Syndrome X","Diabetes Mellitus","RECRUITING","2026-03-18",{"date":34,"type":35},"2026-03-20","ACTUAL",{"date":37,"type":35},"2025-03-17",{"date":39,"type":22},"2026-12",{"name":41,"class":42},"Catholic University of the Sacred Heart","OTHER",2,{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":14,"acronym":15,"eligibilityCriteria":49,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":50,"targetDuration":4,"studyType":23,"phases":51,"briefSummary":52,"conditions":53,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":55,"lastUpdatePostDateStruct":56,"startDateStruct":58,"completionDateStruct":60,"leadSponsor":61,"locationsCount":63},"100604896","identification-of-a-score-for-the-assessment-of-intrapancreatic-fat-100604896","NCT07155473","Identification of a Score for the Assessment of Intrapancreatic Fat","Exclusion Criteria\n\n* Age \\\u003C18 years or \\>80 years\n* History of diabetes treated with insulin\n* HbA1c \\>10% or fasting glucose \\>250 mg\u002FdL\n* Pancreatic diseases (solid tumors\u002Fsecretory NETs\u002Fcystic fibrosis; non-secretory NETs and IPMN may be included)\n* Previous pancreatic surgery\n* Moderate anemia (Hb \\\u003C10 mg\u002FdL)\n* Severe liver failure (Child-Pugh C)\n* Non-metabolic causes of NAPLD (e.g., corticosteroid therapy, antiretrovirals, gemcitabine, octreotide, history of hemochromatosis, malnutrition, HBV\u002FHIV infections)\n* Alcohol abuse (\\>30 g\u002Fday of ethanol)\n* Pregnancy and breastfeeding\n* Inability to adequately understand informed consent and study procedures\n\nInclusion Criteria:\n\n* Age between 18 and 80 years\n* HbA1c \\\u003C10% or fasting glucose \\\u003C250 mg\u002FdL\n* Ability to understand and provide informed consent regarding the procedures, data collection, and analysis.",{"count":21,"type":22},[25],"The SPES clinical study aims to evaluate the relationship between pancreatic fat accumulation (pancreatic steatosis) and metabolic health. Pancreatic steatosis has been linked to conditions like type 2 diabetes (T2D) and metabolic syndrome, but the underlying mechanisms and its impact on beta-cell function remain poorly understood.\n\nThe primary goal of this study is to develop a quantitative ultrasound elastography score to measure the degree of pancreatic steatosis and explore how this relates to pancreatic beta-cell function and key factors associated with the development of type 2 diabetes and metabolic syndrome.\n\nA secondary goal is to categorize participants into four risk classes for type 2 diabetes based on their metabolic profiles and correlate these classes with the degree of pancreatic steatosis. This may provide insights into individual risk stratification for T2D and related complications.\n\nThe study will enroll 100 participants, aged 18 to 80, attending the Endoscopic Ultrasound Unit at the Fondazione Policlinico Universitario Agostino Gemelli in Rome. Participants will undergo endoscopic ultrasound for various clinical reasons, excluding those with pancreatic tumors, cystic fibrosis, or insulin-treated diabetes. Key inclusion criteria include controlled blood glucose levels (HbA1c \\\u003C 10% or fasting glucose \\\u003C 250 mg\u002FdL) and the ability to understand and provide informed consent.\n\nThe study is interventional but does not involve drugs or medical devices. Participants will attend a visit where medical history, physical measurements (e.g., BMI, waist circumference, blood pressure), glucose tolerance tests, and blood work will be collected. This comprehensive approach aims to better understand the metabolic implications of pancreatic steatosis and its role in type 2 diabetes development.\n\nThe study will last 24 months, including the enrollment period. Findings may contribute to improved risk stratification, prevention, and management strategies for type 2 diabetes and related conditions.",[28,29,54],"Diabetes","2025-08-27",{"date":57,"type":35},"2025-09-04",{"date":59,"type":35},"2025-03-01",{"date":39,"type":22},{"name":62,"class":42},"Fondazione Policlinico Universitario Agostino Gemelli IRCCS",1,{"id":65,"slug":66,"hasResults":11,"nctId":67,"briefTitle":68,"officialTitle":68,"acronym":69,"eligibilityCriteria":70,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":71,"targetDuration":4,"studyType":23,"phases":73,"briefSummary":74,"conditions":75,"keywords":82,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":93,"lastUpdatePostDateStruct":94,"startDateStruct":96,"completionDateStruct":98,"leadSponsor":100,"locationsCount":103},"100566936","evaluation-of-a-new-ultrasound-system-for-the-non-invasive-assessment-of-liver-steatosis-in-masldmash-patients-100566936","NCT06661655","Evaluation of a New Ultrasound System for the Non-invasive Assessment of Liver Steatosis in MASLD\u002FMASH Patients","ACOUSTIQ","Inclusion Criteria:\n\n* Adult patient below 80 yo\n* Patients with MASLD\u002FMASH recruited in interventional trials requiring MRI PDFF +\u002F- MRE per interventional protocol, OR\n* Patients with MASLD\u002FMASH recruited in prospective cohorts requiring MRI PDFF +\u002F- MRE per interventional protocol, OR\n* Patients referred to MRI-PDFF or MRE.\n* Patients who consented in written to participate in the study\n* Patients with ongoing social security coverage\n\nExclusion Criteria:\n\n* Patient in their minority (less than 18 yo) or older than 80 yo,\n* Patient with active implants,\n* Patient presenting with a wound where the Hepatoscope exam shall be performed (abdominal right upper quadrant)\n* Patient with a history of decompensated cirrhosis,\n* Patient with a history of hepatocellular carcinoma,\n* Adult patient under tutorship, or unable to express informed consent,\n* Pregnant or breast-feeding\n* Person deprived from their liberty\n* Patient hospitalized without providing consent or in case of an emergency\n* Patient presenting with another know liver disease",{"count":72,"type":22},120,[25],"The objective of the study is to evaluate an ultraportable ultrasound device, Hepatoscope, for the non-invasive assessment of hepatic steatosis in patients with metabolic-dysfunction associated liver diseases (MASLD), by comparing its measurements with current diagnostic modalities, such as MRI-PDFF.",[29,76,77,78,79,80,81],"Fatty Liver","MASH - Metabolic Dysfunction-Associated Steatohepatitis","MASLD","NASH (Non-Alcoholic Steatohepatitis)","Steatosis, Liver","NAFLD",[83,84,85,86,87,88,89,90,91,92],"Liver","Fibrosis","Steatosis","Elastography","Ultrasound","Attenuation","Backscattering coefficient","Sound speed","MRI PDFF","Hepatoscope","2025-08-12",{"date":95,"type":35},"2025-08-15",{"date":97,"type":35},"2025-07-24",{"date":99,"type":22},"2026-09-01",{"name":101,"class":102},"E-Scopics","INDUSTRY",3,{"id":105,"slug":106,"hasResults":11,"nctId":107,"briefTitle":108,"officialTitle":109,"acronym":4,"eligibilityCriteria":110,"healthyVolunteers":11,"sex":17,"minAge":111,"maxAge":112,"enrollmentInfo":113,"targetDuration":4,"studyType":23,"phases":115,"briefSummary":116,"conditions":117,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":122,"lastUpdatePostDateStruct":123,"startDateStruct":125,"completionDateStruct":127,"leadSponsor":129,"locationsCount":43},"100570041","lifestyle-changes-in-older-adults-with-metabolic-syndrome-and-tinnitus-100570041","NCT06702085","Lifestyle Changes in Older Adults With Metabolic Syndrome and Tinnitus","Effects of Lifestyle Changes on Tinnitus in Older Adults With Metabolic Syndrome","Inclusion Criteria:\n\n* obese person (class one obesity)\n* patients with metabolic syndrome\n* patients with chronic subjective tinnitus (bilateral complaint from more than six months).\n* older adults aging 65 years and more\n* both sexes will be included\n\nExclusion Criteria:\n\n* respiratory insult\n* cardiac insult\n* liver insult\n* kidney insult\n* lower limb insult\n* neurological insult","65 Years","75 Years",{"count":114,"type":22},60,[25],"The problem of tinnitus (subjective type) is prevalent in obese older adults with different diseases such as metabolic syndrome. The changes of lifestyle are very important to lose weight, improve tinnitus and metabolic syndrome",[118,29,119,120,121],"Tinnitus","Obesity","Elderly","Weight Loss","2024-11-20",{"date":124,"type":35},"2024-11-22",{"date":126,"type":35},"2024-01-01",{"date":128,"type":22},"2025-01-01",{"name":130,"class":42},"Cairo University",{"id":132,"slug":133,"hasResults":11,"nctId":134,"briefTitle":135,"officialTitle":136,"acronym":137,"eligibilityCriteria":138,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":139,"targetDuration":4,"studyType":23,"phases":141,"briefSummary":142,"conditions":143,"keywords":145,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":151,"lastUpdatePostDateStruct":152,"startDateStruct":154,"completionDateStruct":156,"leadSponsor":158,"locationsCount":63},"100566112","nursing-intervention-in-weight-and-metabolic-syndrome-management-in-first-episode-psychosis-metakop-100566112","NCT06650943","Nursing Intervention in Weight and Metabolic Syndrome Management in First-episode Psychosis (MetaKOP)","Efficacy Study on Nursing Consultation in Weight and Metabolic Syndrome Management Based on the Carbohydrate-insulin Theory in Individuals with First-episode Psychosis (MetaKOP)","MetaKOP","Inclusion Criteria:\n\n1. Patients admitted to the Early Intervention Program (EIP).\n2. First-episode psychosis (FEP) within the last 5 years.\n3. Diagnosis of psychosis from the F2 spectrum or an affective disorder with psychotic symptoms according to ICD-10.\n\nExclusion Criteria:\n\n1. Cognitive inability to learn or comorbid intellectual disability that interferes with study procedures.\n2. Comorbid diagnosis of neurological pathology.\n3. Language or comprehension impairments preventing accurate data collection.\n4. Use of hypoglycemic medication before or during the study.\n5. Refusal to participate",{"count":140,"type":22},88,[25],"The goal of this clinical trial is to evaluate if a nursing intervention based on the carbohydrate-insulin model can effectively reduce weight and manage the risk of metabolic syndrome (MetS) in individuals with first-episode psychosis. The main questions it aims to answer are:\n\nWill the intervention lead to a clinically significant weight loss (≥5%)? Can the intervention improve metabolic parameters, psychopathological state, physical activity level, and quality of life? Researchers will compare participants receiving the specialized nursing consultations to those receiving routine care to see if the former group experiences greater improvements in weight loss and metabolic risk reduction.\n\nParticipants will:\n\nAttend a series of 8 nursing consultations focused on dietary habits based on the carbohydrate-insulin model and physical activity.\n\nComplete assessments at the start, 6 months, and 12 months, including weight, metabolic parameters, and psychological evaluations.",[144,29],"First Episode Psychosis (FEP)",[146,147,148,149,150],"FEP","psychosis","metabolic syndrome","nursing","mental health nurse","2024-10-20",{"date":153,"type":35},"2024-10-22",{"date":155,"type":35},"2023-10-25",{"date":157,"type":22},"2026-06-30",{"name":159,"class":42},"Hospital de Basurto",{"id":161,"slug":162,"hasResults":11,"nctId":163,"briefTitle":164,"officialTitle":165,"acronym":4,"eligibilityCriteria":166,"healthyVolunteers":11,"sex":17,"minAge":167,"maxAge":4,"enrollmentInfo":168,"targetDuration":170,"studyType":171,"phases":4,"briefSummary":172,"conditions":173,"keywords":177,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":181,"lastUpdatePostDateStruct":182,"startDateStruct":184,"completionDateStruct":186,"leadSponsor":188,"locationsCount":43},"100546438","home-blood-pressure-variability-and-its-link-to-arteriosclerosis-and-metabolic-dysfunction-in-hypertensive-patients-100546438","NCT06394934","Home Blood Pressure Variability and Its Link to Arteriosclerosis and Metabolic Dysfunction in Hypertensive Patients","Impact of Home and Clinical Blood Pressure Variability on Arteriosclerosis and Metabolic Indicators","Inclusion Criteria:\n\n1. Adults aged 19 years or older.\n2. Diagnosed with hypertension.\n3. Regular use of antihypertensive medication for at least two years.\n4. Access to a home blood pressure monitor.\n5. Comprehensive medical records available for the past year.\n\nExclusion Criteria:\n\n1\\. Participants who are unable to consent or who might not reliably use the home monitoring app.","19 Years",{"count":169,"type":22},4188,"3 Years","OBSERVATIONAL","This observational study investigates the correlation between home blood pressure variability (BPV) and arteriosclerosis, alongside metabolic indicators, in hypertensive patients over a three-year period. The research specifically focuses on the predictive value of home BPV for major adverse cardiovascular events (MACE) including myocardial infarction, stroke, and heart failure hospitalizations. Utilizing a mobile application called Healthscan for daily BP monitoring, the study aims to enhance the understanding of how BPV impacts cardiovascular and metabolic health in a real-world setting.",[174,175,176,29],"Hypertension","Blood Pressure Monitoring, Home","Arteriosclerosis",[178,179,180,176],"Home Blood Pressure Monitoring","Blood Pressure Variability","Pulse Wave Velocity","2024-04-28",{"date":183,"type":35},"2024-05-01",{"date":185,"type":35},"2024-01-09",{"date":187,"type":22},"2029-12-31",{"name":189,"class":42},"Korea University Anam Hospital",{"id":191,"slug":192,"hasResults":11,"nctId":193,"briefTitle":194,"officialTitle":195,"acronym":4,"eligibilityCriteria":196,"healthyVolunteers":197,"sex":17,"minAge":198,"maxAge":111,"enrollmentInfo":199,"targetDuration":4,"studyType":171,"phases":4,"briefSummary":201,"conditions":202,"keywords":205,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":209,"lastUpdatePostDateStruct":210,"startDateStruct":212,"completionDateStruct":214,"leadSponsor":215,"locationsCount":63},"100241379","the-early-warning-system-for-the-diabetic-encephalopathy-100241379","NCT02420470","The Early Warning System for the Diabetic Encephalopathy","The Early Warning System for the Central Nervous System Micro-structure Alterations During Early Diabetes Based on the Multi-mode MRIs","Inclusion Criteria:\n\n* without dementia\n* Inform Consent Form\n* Education time more than 6 years\n* blood glucose matches the group standard\n\nExclusion Criteria:\n\n* Pregnant woman\n* suffer from serious brain disease\n* Magnetic resonance contraindications\n* lack of compliance\n* image quality is too poor to deal with",true,"40 Years",{"count":200,"type":22},300,"Diabetes( mainly type II diabetes )lead to the central nervous system (CNS) function impairment, especially the mild cognitive impairment that increased the risk of progression to dementia.The primary objectives are defined according to a hierarchical design: i) to tailor and apply multi-parametric, functional MRI techniques to identify cerebral abnormalities (cerebral biomarkers) in type 2 diabetes mellitus and prodromal diabetes mellitus ; ii) to assess whether these cerebral biomarkers are associated with cognitive decrements;iii) to follow up with the putative prediabetic condition patients to verify whether they can transform into diabetes.",[203,204,29],"Diabetes Mellitus Type 2","Mild Cognitive Impairment",[206,207,208],"diabetes","neural and vessel alteration","prodromal stage","2022-07-12",{"date":211,"type":35},"2022-07-13",{"date":213,"type":4},"2015-04",{"date":39,"type":22},{"name":216,"class":42},"Tang-Du Hospital"]